Zobrazeno 1 - 10
of 55
pro vyhledávání: ''
Autor:
Radu Vidra, Snejeana Tintari, Tudor Ciuleanu, Adina Nemes, Andrada Deac, Andreea Vidrean, Sebastian Pintea
Publikováno v:
Experimental and Therapeutic Medicine
The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in bre
Autor:
Hirotake Hida, Mariko Nakamura, Yuna Shiroma, Miku Iwata, Akira Yoshimi, Masayuki Miyazaki, Noriko Tanaka, Aya Torii-Goto, Yukihiro Noda, Kiyofumi Yamada
Publikováno v:
Mol Clin Oncol
Chemotherapy-induced nausea and vomiting (CINV) can cause anorexia, weight loss and deterioration of patient quality of life. It is one of the most unpleasant adverse effects of chemotherapy treatment regimens. For the optimal treatment of gastrointe
Publikováno v:
Molecular Medicine Reports. 16:8563-8571
Fructose-1,6-bisphosphatase-1 (FBP1), a gluconeogenesis rate-limiting enzyme expressed in various tissues, is important in the carcinogenesis of various cancers. To evaluate the association of FBP1 expression and carcinogenesis and chemoresistance in
Autor:
Emi Sato, Masako Ishikawa, Kentaro Nakayama, Tomoka Ishibashi, Hiroshi Katagiri, Kohei Nakamura, Satoru Kyo
Publikováno v:
Molecular and Clinical Oncology. 7:391-394
The prognosis of patients with recurrent/persistent endometrial cancer, particularly type II cancer, remains poor, and effective treatment has not yet been established. We herein present the case of a patient with recurrent type II endometrial cancer
Autor:
Shigehiko Nishimura, Takeo Nishimori, Shigehito Yamagata, Naoyoshi Onoda, Kosei Hirakawa, Tsutomu Takashima, Shinya Tokunaga, Hidemi Kawajiri, Katsumi Ikeda, Satoru Noda, Seika Tei, Kenji Tezuka, Shinichiro Kashiwagi, Yoko Mizuyama, Yoshinari Ogawa, Takeshi Sunami, Minoru Takada, Tetsuro Ishikawa, Shinzoh Kudoh
Publikováno v:
Molecular and Clinical Oncology. 6:534-538
Although the concurrent use of anthracycline-containing chemotherapy and taxane with trastuzumab are considered the treatment of choice for the primary systemic therapy of human epidermal growth factor receptor 2 (HER2)-overexpressing early breast ca
Publikováno v:
Oncology Letters
The present study examined the association between squamous cell carcinoma antigen (SCCA) expression and the response of patients with cervical cancer to docetaxel-carboplatin (DC) combination chemotherapy, in order to determine the prognostic potent
Autor:
Hiroshi Nokihara, Emi Kubo, Yasushi Goto, Noboru Yamamoto, Yuichiro Ohe, Hidehito Horinouchi, Shintaro Kanda, Yutaka Fujiwara
Publikováno v:
Molecular and Clinical Oncology. 6:56-62
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib was initially approved in Japan in 2002 for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC); however, the optimal order of conventional cytotox
Autor:
Dimitra Stefanou, Antigoni Sakellaropoulou, Despina Gkeka, Gavriil Akakios, Marina Gkiaouraki, Alexandros Ardavanis, Sofia Stamatopoulou, Maria Prevezanou
Publikováno v:
Oncology Letters. 12:4635-4642
Data concerning bevacizumab plus pemetrexed plus carboplatin as first-line treatment for patients with non-squamous non-small cell lung cancer (NSCLC) with or without brain metastases (BM) are lacking. The present study analyzed the efficacy and safe
Autor:
Áron Kristóf Ghimessy, Edit Csada, György Losonczy, Zsuzsanna Vennes, Zsuzsanna Sztancsik, Edina Tolnay, László Helf, Péter Dombi, Veronika Sárosi, E. Juhasz
Publikováno v:
Oncology Letters
The previous results of former clinical studies confirmed that first-line bevacizumab (BEV) in combination with chemotherapy improves clinical outcomes in patients with advanced non-squamous non-small cell lung cancer. The AVALANCHE study (ClinicalTr
Autor:
Takako Oteki, Hiroaki Satoh, Gen Ohara, Koichi Kurishima, Asuka Ishikawa, Katsunori Kagohashi, Yoshie Sasaki
Publikováno v:
Experimental and Therapeutic Medicine. 11:243-246
The aim of the present study was to investigate the effect of rikkunshi-to, a Japanese herbal medicine, on post-chemotherapeutic appetite loss. Patients with unresectable lung cancer, who were treated with carboplatin (CBDCA)-containing, cisplatin (C